CAS 407582-49-4
:Acido 2-[4-(2-carbossipropossi)-3-cianofenil]-4-metil-5-tiazolcarbossilico
- 2-[4-(2-Carboxypropoxy)-3-cyanophenyl]-4-methyl-5-thiazolecarboxylic acid
- 5-Thiazolecarboxylic acid, 2-[4-(2-carboxypropoxy)-3-cyanophenyl]-4-methyl-
Ref: 4Z-F-3994
5mgPrezzo su richiesta10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiestaFebuxostat 67M-4
CAS:Prodotto controllatoApplications Febuxostat 67M-4 is a derivative compound of Febuxostat 67M-1 (F229005) which is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and also used to reduce the risk of gout or kidney stone formation.
References Du, J., et al.: Handbook of Metabolic Pathways of Xenobiotics, 4, 1395 (2014)Formula:C16H14N2O5SColore e forma:NeatPeso molecolare:346.36Ref: ST-EA-CP-F7058
10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiestaFebuxostat 67M-4
CAS:Febuxostat 67M-4, a derivative of 67M-1, inhibits xanthine oxidase to lower uric acid and gout/kidney stone risk.Formula:C16H14N2O5SColore e forma:SolidPeso molecolare:346.36Febuxostat 67M-4
CAS:Febuxostat is a potent, selective inhibitor of the enzyme xanthine oxidoreductase (XOR). This enzyme is involved in the production of uric acid and its inhibition leads to a decrease in serum uric acid levels. Febuxostat is used for the treatment of chronic gouty arthritis, hyperuricemia associated with primary or secondary causes, and asymptomatic hyperuricemia.
Febuxostat was shown to bind to a number of different receptors and ion channels, including the purinergic receptor P2Y1, ATP-sensitive potassium channel KATP, transient receptor potential ankyrin 1 channel TRPA1 and TRPV1. It also interacts with peptides such as vasopressin V1a receptor antagonist [8] and alpha-2 adrenergic receptor antagonist [9].Formula:C16H14N2O5SPurezza:Min. 95%Peso molecolare:346.4 g/mol




